Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
Cooke GS, Hung LM, Flower B, McCabe L, Hang VTK, Thu VT, Thuan DT, Dung NT, Phuong LT, Khoa DB, An NTC, Thach PN, Huong VTT, Bich DT, Tuyen NK, Ansari MA, Le Ngoc C, Quang VM, Phuong NTN, Thao LT, Tran NB, Kestelyn E, Kingsley C, Van Doorn R, Rahman M, Pett SL, Thwaites GE, Barnes E, Day JN, Chau NVV, Walker AS
- DOI
- 10.1016/S0140-6736(25)00097-2
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/aa776395-f75d-4f00-842e-34120838daef is authoritative.
How this rating was calculated
- StatisticsStatistic did not reproduce−0.5★
- IntegrityIntegrity concern−0.5★
- ClaimsOverstated claim−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 4 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
- 01Printed percentage does not match its own count
98.7% does not match the reported count 151/152
“151/152 (98.7%)”
- 02Efficacy rests on an unvalidated surrogate endpoint
The primary efficacy endpoint is sustained virological response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion. SVR is a surrogate marker for clinical outcomes such as prevention of cirrhosis, hepatocellular carcinoma, and mortality. The manuscript does not provide evidence linking SVR to these hard clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the surrogate itself. Therefore, the efficacy claim rests on a surrogate without a validated link to clinical benefit.
“The primary endpoint was SVR, defined as plasma HCV RNA less than the lower level of quantification 12 weeks after the end of treatment without previous treatment failure.”
- 03Conclusion reaches beyond the evidence
The induction–maintenance strategy is cost-saving.
“When treatment costs are proportional to the number of tablets used, the induction and maintenance strategy would be cost saving, although this is not the primary intent of the strategy.”
Discussion ¶8Find in source
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and thoroughly reported randomised controlled non-inferiority trial. The design is rigorous, ethical approvals are documented, and statistical methods are appropriate. Minor reporting gaps include threshold p-values, lack of explicit CONSORT statement, and absence of code sharing, but these do not undermine the overall integrity.
Both reviewers agreed on study type and all dimension statuses. The statistics verification component checked only 2 tests (1 consistent, 1 not flagged as error), so the statistical analysis is not fully verified. The citation check found no retracted or missing references. The claim audit flagged one overstated claim about cost-saving, which is addressed in the action items.
Numerical inconsistencies
2 findings · worst highValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
- Internal contradictions in the reported numbersAssessed
Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT).
- PERCENT98.7% does not match the reported count 151/152
“151/152 (98.7%)”
- CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Check the p-value for the comparison of adverse reactions between 4-week antiviral plus interferon and SOC groups.
“Adverse reactions were uncommon in the SOC (five [3%] of 154), induction–maintenance (six [4%] of 156), and RGT groups (five [3%] of 159), but very common in the 4-week antiviral plus interferon group (109 [70%] of 156; appendix p 35).”
Taken as given: The numbers 109 and 47 are the event and non-event counts in the 4-week antiviral plus interferon group (156 total).; The numbers 5 and 149 are the event and non-event counts in the SOC group (154 total).; The p-value is from a two-sided chi-square test.Method: Two-sided Pearson chi-square test on the 2x2 table.How we recomputed it: pChi2x2(109, 47, 5, 149)
- lowinternal contradictionThe abstract states 624 participants were randomised, but the results section states 646 were randomly assigned and 22 excluded, which is consistent. However, the baseline table shows n=313 for sofosbuvir–velpatasvir and n=311 for sofosbuvir–daclatasvir, summing to 624, which is consistent. No contradiction found.
“624 participants were randomised (470 [75%] were male and 154 [25%] were female).”
AbstractFind in source
Overstated conclusions
2 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Conclusions overstated beyond the evidenceAssessed
7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).
- overstatedReviewer 1The induction–maintenance strategy is cost-saving.The paper states that when treatment costs are proportional to the number of tablets used, the strategy would be cost-saving, but this is a conditional statement and not a definitive claim.Evidence: The discussion mentions cost-saving only under a specific condition.
“When treatment costs are proportional to the number of tablets used, the induction and maintenance strategy would be cost saving, although this is not the primary intent of the strategy.”
Discussion ¶8Find in source - supportedReviewer 1Sofosbuvir–daclatasvir is non-inferior to sofosbuvir–velpatasvir.The primary outcome analysis shows a risk difference of 2.2% with 90% CrI within the 5% non-inferiority margin, supporting non-inferiority.Evidence: SVR occurred in 294 (97%) of 302 in the sofosbuvir–daclatasvir group and 292 (95%) of 307 in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% CrI –0·2 to 4·8).
“SVR occurred in 294 (97%) of 302 participants in the sofosbuvir–daclatasvir group and 292 (95%) of 307 participants in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% credible interval [CrI] –0·2 to 4·8, within the 5% non-inferiority margin; 93% probability that sofosbuvir–daclatasvir is superior to sofosbuvir–velpatasvir).”
Results ¶3Find in source - supportedReviewer 1Novel treatment strategies are non-inferior to standard of care.All three novel strategies had risk differences within the 10% non-inferiority margin, supporting non-inferiority.Evidence: SVR occurred in 148 (99%) of 150 in the SOC group, 143 (94%) of 152 in the 4-week antiviral plus interferon group (–4·5%, 90% CrI –8·3 to –1·3), 151 (99%) of 152 in the induction–maintenance group (0·6%, –1·1 to 2·7), and 144 (93%) of 155 in the RGT group (–5·7%, –9·6 to –2·3); all risk differences were within the 10% non-inferiority margin.
“SVR occurred in 148 (99%) of 150 in the SOC group, 143 (94%) of 152 in the 4-week antiviral plus interferon group (–4·5%, 90% CrI –8·3 to –1·3), 151 (99%) of 152 in the induction–maintenance group (0·6%, –1·1 to 2·7), and 144 (93%) of 155 in the RGT group (–5·7%, –9·6 to –2·3); all risk differences were within the 10% non-inferiority margin.”
Results ¶3Find in source - supportedReviewer 1Sofosbuvir–daclatasvir has a 93% probability of being superior to sofosbuvir–velpatasvir.The Bayesian analysis provides a 93% probability, which is directly reported and supports the claim.Evidence: The primary analysis reports a 93% probability of higher efficacy from sofosbuvir–daclatasvir versus sofosbuvir–velpatasvir.
“with a 93% probability of higher efficacy from sofosbuvir–daclatasvir versus sofosbuvir–velpatasvir”
Results ¶3Find in source - supportedReviewer 2Sofosbuvir–daclatasvir was non-inferior to sofosbuvir–velpatasvir.The primary outcome analysis shows the risk difference and credible interval within the non-inferiority margin, supporting the claim.Evidence: SVR occurred in 294 (97%) of 302 in the sofosbuvir–daclatasvir group and 292 (95%) of 307 in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% CrI –0·2 to 4·8).
“Sofosbuvir–daclatasvir was non-inferior to sofosbuvir–velpatasvir.”
AbstractFind in source - supportedReviewer 2High efficacy was seen with novel strategies.The SVR rates for the novel strategies were high and within the non-inferiority margin, supporting the claim.Evidence: SVR occurred in 148 (99%) of 150 in the SOC group, 143 (94%) of 152 in the 4-week antiviral plus interferon group, 151 (99%) of 152 in the induction–maintenance group, and 144 (93%) of 155 in the RGT group; all within the 10% non-inferiority margin.
“High efficacy was seen with novel strategies, which might help to inform approaches to treatment for harder-to-reach populations.”
AbstractFind in source - supportedReviewer 2Sofosbuvir–daclatasvir had a 93% probability of higher efficacy than sofosbuvir–velpatasvir.The Bayesian analysis provides a 93% probability, which is directly reported and supports the claim.Evidence: 93% probability that sofosbuvir–daclatasvir is superior to sofosbuvir–velpatasvir.
93% probability that sofosbuvir–daclatasvir is superior to sofosbuvir–velpatasvir.
Abstractreviewer’s wording
Premise concern: surrogate not validated for clinical benefit.
- INADEQUATESurrogate endpointThe primary efficacy endpoint is sustained virological response (SVR), defined as undetectable HCV RNA 12 weeks after treatment completion. SVR is a surrogate marker for clinical outcomes such as prevention of cirrhosis, hepatocellular carcinoma, and mortality. The manuscript does not provide evidence linking SVR to these hard clinical outcomes, nor does it demonstrate target engagement at the tested dose beyond the surrogate itself. Therefore, the efficacy claim rests on a surrogate without a validated link to clinical benefit.
“The primary endpoint was SVR, defined as plasma HCV RNA less than the lower level of quantification 12 weeks after the end of treatment without previous treatment failure.”
- ADEQUATEEffect sizeThe primary effect sizes are reported as SVR rates of 97% and 95% for the two drug regimens, and 99%, 94%, 99%, and 93% for the four treatment strategies. These are high cure rates, and the non-inferiority margins (5% and 10%) provide a clinical anchor for meaningfulness. The differences between groups are small and within the pre-specified margins, indicating that the effects are clinically meaningful.
“SVR occurred in 294 (97%) of 302 participants in the sofosbuvir–daclatasvir group and 292 (95%) of 307 participants in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% credible interval [CrI] –0·2 to 4·8, within the 5% non-inferiority margin; 93% probability that sofosbuvir–daclatasvir is superior to sofosbuvir–velpatasvir).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites WHO guidelines and notes the lack of randomised trials comparing the two regimens, establishing the need for the study. The rationale for testing novel strategies is supported by the need to expand access to treatment. Limitations of prior research are implicitly addressed by the trial design, though not explicitly detailed.
“No randomised trials have compared these treatment combinations and, in the absence of head-to-head comparisons and with high variability in generic pricing, countries differ in their choice of first-line treatment.”
“In this Article, we describe the first randomised controlled trial of WHO-approved first-line treatments for HCV, designed to assess non-inferiority of sofosbuvir–daclatasvir versus sofosbuvir–velpatasvir, and to evaluate potential novel treatment strategies that could expand access to treatment using an efficient platform factorial design.”
“No randomised trials have compared these treatment combinations and, in the absence of head-to-head comparisons and with high variability in generic pricing, countries differ in their choice of first-line treatment.”
“In this Article, we describe the first randomised controlled trial of WHO-approved first-line treatments for HCV, designed to assess non-inferiority of sofosbuvir–daclatasvir versus sofosbuvir–velpatasvir, and to evaluate potential novel treatment strategies that could expand access to treatment using an efficient platform factorial design.”
Randomization used a computer-generated sequential list with permuted blocks, stratified by centre and genotype. The trial was open-label with a clear rationale, and efficacy endpoints were assessed by masked laboratory staff. Sample size calculations were provided for both the drug and strategy comparisons. Inclusion/exclusion criteria were specified, and the analysis populations (mITT, safety, per-protocol) were defined. Outlier handling is addressed through the definition of treatment failure and the per-protocol population.
“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”
“The trial was open-label: no placebo was provided due to the complexity of ensuring that participants took the right pills on the right days. Masking of trial staff from randomised assignment was not possible, but efficacy endpoints were based on HCV viral loads assessed in the laboratory by masked individuals.”
“Second, random assignment of 624 participants provided 88% power to demonstrate non-inferiority between treatment combinations based on a non-inferiority margin of 5%, and 99% power to demonstrate non-inferiority between treatment strategies based on a non-inferiority margin of 10%, assuming 95% SVR, a one-sided α of 0·05, and 5% loss to follow-up.”
“Randomisation used a computer-generated sequential list with variably sized permuted blocks prepared by the trial statistician (LM) and incorporated securely into the online trial database.”
“The trial was open-label: no placebo was provided due to the complexity of ensuring that participants took the right pills on the right days. Masking of trial staff from randomised assignment was not possible, but efficacy endpoints were based on HCV viral loads assessed in the laboratory by masked individuals.”
“Second, random assignment of 624 participants provided 88% power to demonstrate non-inferiority between treatment combinations based on a non-inferiority margin of 5%, and 99% power to demonstrate non-inferiority between treatment strategies based on a non-inferiority margin of 10%, assuming 95% SVR, a one-sided α of 0·05, and 5% loss to follow-up.”
Sex is reported for all participants, and age is reported as median with IQR. HCV genotype is reported in detail. Health status is described via inclusion criteria (mild-to-moderate liver fibrosis) and baseline characteristics. Demographics include age, sex, HIV status, and substance use history. Ethnicity was not collected, which is noted.
“154 (25%) patients were female”
“Median age was 42 years (IQR 37–51)”
“we did not collect data on ethnicity”
“Median age was 42 years (IQR 37–51), 154 (25%) patients were female, 84 (13%) were HIV positive (and receiving treatment, in line with the inclusion criteria), and 213 (34%) had a history of illicit substance use.”
“Data on sex (male or female) were collected by self-report; we did not collect data on ethnicity.”
The paper states ethical approval was obtained from local hospital ethics committees, the Ministry of Health, and UK institutions, with a reference number. Written informed consent was obtained from participants. Regulatory compliance is implied through adherence to ethical standards, though not explicitly named.
“Ethical approval was obtained from local hospital ethics committees at the Hospital for Tropical Diseases and the National Hospital of Tropical Disease; the Ministry of Health, Viet Nam; Imperial College London, UK; and the University of Oxford, UK (ref 110-0319/35CN).”
“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”
“Ethical approval was obtained from local hospital ethics committees at the Hospital for Tropical Diseases and the National Hospital of Tropical Disease; the Ministry of Health, Viet Nam; Imperial College London, UK; and the University of Oxford, UK (ref 110-0319/35CN).”
“Participants were recruited by the trials team from routine clinics and provided written informed consent before random assignment.”
The drugs (sofosbuvir, daclatasvir, velpatasvir, PEGylated interferon) are identified with doses and manufacturers. The viral load assays are identified with manufacturers. Statistical software (R and Stata) is named with versions. No antibodies, cell lines, or mycoplasma testing are applicable.
“All trial drugs were purchased at market prices through generic suppliers (direct-acting antivirals from Mylan, Mumbai, India; PEGylated interferon alfa-2a from Zuillig Pharma, Ho Chi Minh City, Viet Nam).”
“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0”
“All trial drugs were purchased at market prices through generic suppliers (direct-acting antivirals from Mylan, Mumbai, India; PEGylated interferon alfa-2a from Zuillig Pharma, Ho Chi Minh City, Viet Nam).”
“Bayesian analyses were done with R version 4.1.3, all other analyses were done using Stata version 18.0 (appendix pp 5–6).”
The primary analysis used Bayesian methods with uninformative priors, reporting risk differences and 90% CrIs. Secondary analyses used frequentist methods. Tests are named (e.g., χ², exact tests, GEE, interval regression). Assumptions are addressed through the choice of methods. Exact p-values are reported for some comparisons, but many are reported as Bayesian probabilities. Effect sizes with CIs are reported. Software is identified. Data presentation includes per-group n and percentages.
“The proportion of participants with undetectable HCV viral load at each visit was analysed using χ 2 or exact tests and binomial generalised estimating equations with an independent correlation structure”
“SVR occurred in 294 (97%) of 302 participants in the sofosbuvir–daclatasvir group and 292 (95%) of 307 participants in the sofosbuvir–velpatasvir group (risk difference 2·2%, 90% credible interval [CrI] –0·2 to 4·8”
“Primary comparisons between randomised groups were analysed using Bayesian methods with uninformative priors, calculating marginal risk differences and 90% credible intervals (CrIs) after logistic regression, reflecting the non-inferiority design, since it is implausible that giving less treatment could lead to better outcomes.”
“adverse reactions were very common in the 4-week antiviral plus interferon group compared with the other treatment strategies (risk difference vs SOC group, 66·8% [59·2 to 74·0]; p<0·0001).”
The data sharing statement describes a controlled access approach via the OUCRU Data Access Committee, with a data access request form and agreement. This is a concrete route for accessing de-identified individual participant data. No code sharing is mentioned, but the statistical analysis is described in detail.
“All individual participant data collected during the trial, after de-identification, will therefore be available (with data dictionaries), as will the trial protocol and statistical analysis plan, from immediately following publication with no end date. Anyone wishing to access the data should contact dac@oucru.org to gain access; data requestors will need to complete a short data access request form (available from https://www.oucru.org/data-sharing-policy/ ), which will be reviewed and approved by the OUCRU Data Access Committee, and sign a data access agreement.”
“All individual participant data collected during the trial, after de-identification, will therefore be available (with data dictionaries), as will the trial protocol and statistical analysis plan, from immediately following publication with no end date. Anyone wishing to access the data should contact dac@oucru.org to gain access; data requestors will need to complete a short data access request form (available from https://www.oucru.org/data-sharing-policy/ ), which will be reviewed and approved by the OUCRU Data Access Committee, and sign a data access agreement.”
The trial is registered with ISRCTN. Methods are described in detail, including procedures and statistical analysis. Limitations are explicitly discussed, including lack of masking, limited generalisability, and potential for re-infection. Conclusions are appropriately cautious, noting the need for further studies. Funding and conflicts of interest are declared.
“This trial is registered with ISRCTN, 61522291.”
“Limitations of this study include the fact that the trial only included individuals with mild to moderate liver disease; cure rates in those with more advanced fibrosis or cirrhosis will be lower and further work is needed to establish the role of shorter-course treatment in such individuals.”
“This trial is registered with ISRCTN, 61522291, and is completed.”
“Limitations of this study include the fact that the trial only included individuals with mild to moderate liver disease; cure rates in those with more advanced fibrosis or cirrhosis will be lower and further work is needed to establish the role of shorter-course treatment in such individuals.”
Registration stated in text, but no registry ID was detected. Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 23 references by DOI: 11 verified — 12 no DOI (shown, not verified).
- NO DOIGlobal health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHCV market intelligence report issue 3No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOITreatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIUpdated recommendation on treatment of adolescents and children with chronic HCV infection and HCV simplified service delivery and diagnosticsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIHepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infectionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIAccelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIIntermittent regimens for tuberculosis treatment: back to the future?No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIVariable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCTNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEASL recommendations on treatment of hepatitis C: final update of the seriesNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIPegylated interferon alpha 2a for the treatment of hepatitis C virus infectionNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIFour weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trialNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIGenetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
1 data/code link checked; 1 live.
- datahttps://www.oucru.org/data-sharing-policy/LIVEHTTP 200Resolves, but the content could not be matched to the paper.
Copyediting
5 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 5 minor suggestions below.
5 copyedit issues flagged: mostly consistency, typo.
- MINORtypoTable 2, header“4-week acting plus interferon”→ 4-week antiviral plus interferonTypo in table header.
- MINORconsistencyTable 2, primary efficacy comparison“·4·5% (–8·3 to –1·3); P=0·99”→ –4·5% (–8·3 to –1·3); P=0·99Missing minus sign in the risk difference.
- MINORconsistencyTable 3, risk difference in adverse reactions“2–3% (–1·9 to 6·3); P=0·14”→ 2·3% (–1·9 to 6·3); P=0·14Inconsistent decimal formatting.
- MINORconsistencyTable 3, risk difference in adverse reactions“66·8% (59–2 to 74·0); P<0·0001”→ 66·8% (59·2 to 74·0); P<0·0001Inconsistent decimal formatting.
- MINORconsistencyTable 2, secondary outcomes“150/150 (100’0%)”→ 150/150 (100·0%)Inconsistent use of apostrophe instead of middle dot.
The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (threshold p-values, lack of explicit CONSORT statement, no code sharing) and the overstated cost-saving claim. No erratum is warranted for the core findings, but the authors should consider issuing a correction for the table typos and tempering the cost-saving claim.
- 1.HIGHreportingIn the Discussion, temper the claim that the induction–maintenance strategy is cost-saving to reflect that it is conditional on treatment costs being proportional to the number of tablets used.The claim audit rated this as overstated; the paper only supports a conditional statement, not a definitive cost-saving claim.
- 2.HIGHstatisticsIn the Abstract and Results, replace threshold p-values (e.g., p<0·0001) with exact p-values where available, or provide them in the appendix.Exact p-values improve transparency and allow readers to assess the strength of evidence.
- 3.MEDIUMreportingIn the Methods or Acknowledgments, explicitly state adherence to the CONSORT reporting guideline.The trial is registered and includes a CONSORT diagram, but the guideline is not named, which is a minor reporting gap.
- 4.MEDIUMdata codeIn the Data sharing statement, add a statement about the availability of statistical analysis code, even if standard software was used.Enhances reproducibility and aligns with best practices for data-driven research.
- 5.MEDIUMstatisticsIn the Statistical analysis section, clarify the handling of missing data for the primary outcome, including any imputation methods.The modified ITT population is defined, but imputation methods are not described, which is a common reviewer request.
- 6.MEDIUMreportingIn the Methods, provide more detail on randomization sequence generation and allocation concealment to fully meet CONSORT requirements.Reviewer 2 noted this as a gap; it strengthens the transparency of the randomization process.
- 7.MEDIUMcopyeditIn Table 2, fix the typo in the header: change '4-week acting plus interferon' to '4-week antiviral plus interferon'.Corrects a clear typo that could confuse readers.
- 8.MEDIUMcopyeditIn Table 2, correct the missing minus sign in the primary efficacy comparison: change '·4·5%' to '–4·5%'.The risk difference is negative and the missing sign is a factual error.
- 9.MEDIUMcopyeditIn Table 3, fix the decimal formatting inconsistencies: change '2–3%' to '2·3%' and '59–2' to '59·2'.Ensures consistency and accuracy in reported values.
- 10.MEDIUMcopyeditIn Table 2, replace the apostrophe in '100’0%' with a middle dot: '100·0%'.Consistent decimal formatting is expected in scientific tables.
- 11.LOWreportingIn the Discussion, explicitly address how the lack of blinding might have influenced the results, beyond stating it was not possible.Reviewer 1 suggested this; it would strengthen the interpretation of the open-label design.
- 12.LOWdata codeIn the Data sharing statement, specify the timeframe for data availability and any conditions for access beyond the data access agreement.Provides clarity for potential data requestors.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.